Edition:
United Kingdom

People: La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

16.16USD
19 Oct 2018
Change (% chg)

$-0.83 (-4.89%)
Prev Close
$16.99
Open
$17.06
Day's High
$17.28
Day's Low
$15.56
Volume
249,582
Avg. Vol
132,836
52-wk High
$41.24
52-wk Low
$15.56

Chawla, Lakhmir 

Dr. Lakhmir S. Chawla is the Chief Medical Officer of the Company. He has more than 20 years of medical experience with particular expertise in critical care and nephrology. Dr. Chawla has been an active investigator in the field of critical care nephrology since 2002. Previously, Dr. Chawla was an Associate Professor of Medicine at the George Washington University from 2008 to 2015, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla was also the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center from 2014 to 2015. During his tenure at George Washington, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial, which served as the basis for the Company’s ongoing ATHOS 3 clinical study. Dr. Chawla received an M.D. from the New Jersey Medical School.

Basic Compensation

Total Annual Compensation, USD 647,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,528,550
Fiscal Year Total, USD 2,175,550

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Kevin Tang

217,635

George Tidmarsh

6,450,640

Dennis Mulroy

2,014,040

Jennifer Carver

2,092,220

James Rolke

1,996,670

Lakhmir Chawla

2,175,550
As Of  31 Dec 2017